An open-label, multicenter, prospective, single-arm, exploratory study to assess role of pancreatic enzyme replacement therapy (PERT) (Creon 25,000) in patients with Pancreatic Exocrine Insufficiency (PEI) after total gastrectomy.
Latest Information Update: 29 Sep 2025
At a glance
- Drugs Pancrelipase (Primary)
- Indications Exocrine pancreatic insufficiency
- Focus Therapeutic Use
- Sponsors Viatris
Most Recent Events
- 25 Sep 2025 New trial record